STOCK TITAN

Immatics N.V SEC Filings

IMTX NASDAQ

Welcome to our dedicated page for Immatics N.V SEC filings (Ticker: IMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Scanning hundreds of pages to see whether Immatics still has cash to fund its next TCER® trial or how collaboration revenue affects runway can feel impossible. The company’s biotech disclosures combine scientific jargon with intricate milestone accounting—making each Immatics SEC filing a daunting read.

Stock Titan solves that problem. Our AI-powered summaries turn the Immatics annual report 10-K simplified into a concise overview of cash burn and pipeline status, while every Immatics quarterly earnings report 10-Q filing is annotated with margin trends and R&D detail. Real-time alerts flag Immatics Form 4 insider transactions seconds after they hit EDGAR, so you never miss executive stock moves before critical data releases.

  • Immatics insider trading Form 4 transactions parsed into easy-to-filter tables
  • Immatics proxy statement executive compensation distilled to pay vs. performance metrics
  • Immatics 8-K material events explained with plain-English AI notes on trial setbacks or partnership wins
  • Side-by-side Immatics earnings report filing analysis across quarters to spot cash-runway shifts

Whether you’re understanding Immatics SEC documents with AI for the first time or monitoring seasoned positions, our platform delivers:

Comprehensive coverage of every form type, real-time updates as they post to EDGAR, and expert context that links pipeline science to financial impact. Gain clarity on Immatics executive stock transactions Form 4, uncover hidden risk factors, and track milestones without wading through technical prose. Immatics filings, explained simply—so you can focus on making informed decisions.

Rhea-AI Summary
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
registration

FAQ

What is the current stock price of Immatics N.V (IMTX)?

The current stock price of Immatics N.V (IMTX) is $5.9 as of July 9, 2025.

What is the market cap of Immatics N.V (IMTX)?

The market cap of Immatics N.V (IMTX) is approximately 673.4M.

What is the core focus of Immatics N.V?

Immatics N.V is focused on developing T-cell redirecting immunotherapies for the treatment of cancer. Its research emphasizes innovative adoptive cell therapies and bispecific TCR molecules to target tumor antigens.

How does Immatics generate revenue?

The company generates revenue primarily through strategic collaborations and licensing agreements with established pharmaceutical and biotechnology companies. This approach leverages its proprietary technologies rather than relying solely on product sales.

What distinguishes Immatics' technology platforms?

Immatics utilizes proprietary technology platforms, such as its Xpresient® system, to identify and validate novel tumor targets. This innovative approach underpins the development of its advanced therapeutic candidates, including TCER® molecules.

What are TCER® molecules and why are they significant?

TCER® molecules are bispecific biologics designed to engage T-cells and direct them against cancer cells. They are engineered to maximize efficacy while reducing toxicities, representing a novel approach in immunotherapy.

How does the company position itself within the competitive immunotherapy landscape?

Immatics differentiates itself through its focus on novel tumor targets and unique therapeutic candidates. Its strategic collaborations and rigorous scientific methodology contribute to a distinctive positioning in precision oncology.

What types of cancer does Immatics target?

The company targets a broad range of cancers, encompassing both solid and liquid tumors. Its research is centered on discovering and validating targets that are relevant across multiple tumor types.

How does Immatics ensure the safety and efficacy of its therapies?

Safety and efficacy are prioritized through rigorous preclinical and clinical evaluations. The design of its therapeutic candidates, such as the dual-domain structure of TCER® molecules, is specifically intended to optimize the balance between potent anti-tumor activity and manageable safety profiles.

What role do strategic collaborations play in Immatics' business model?

Strategic collaborations are central to Immatics' business model. They facilitate resource sharing, accelerate clinical development, and enable the company to leverage external expertise, thereby enhancing the overall value of its innovative platforms.
Immatics N.V

NASDAQ:IMTX

IMTX Rankings

IMTX Stock Data

673.39M
80.02M
22.17%
87.52%
7.11%
Biotechnology
Healthcare
Link
Germany
Tübingen